loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for dextrosimendan

    Client Email Product
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    dextrosimendan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 431,861Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tenax Therapeutics Reports Q2 2024 Results And Corporate Update
    Tenax Therapeutics Reports Q2 2024 Results And Corporate Update

    13 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/13/2929628/0/en/Tenax-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Provides-a-Corporate-Update.html

    GLOBENEWSWIRE
    13 Aug 2024
    Share Share
    Tenax New Patent for Levosimendan in PH-HFpEF
    Tenax New Patent for Levosimendan in PH-HFpEF

    30 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/30/2872119/0/en/Tenax-Therapeutics-Announces-New-U-S-Patent-Covering-the-Use-of-Levosimendan-in-Pulmonary-Hypertension-with-Heart-Failure-with-Preserved-Ejection-Fraction-PH-HFpEF.html

    GLOBENEWSWIRE
    30 Apr 2024
    Share Share
    Tenax Therapeutics Hosts KOL Event
    Tenax Therapeutics Hosts KOL Event

    09 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/09/2859987/0/en/Tenax-Therapeutics-to-Host-KOL-Event-LEVEL-Setting-the-Scientific-Rationale-for-Levosimendan-as-a-Potential-First-Treatment-for-PH-HFpEF-and-the-Ongoing-Phase-3-LEVEL-Study.html

    GLOBENEWSWIRE
    09 Apr 2024
    Share Share
    Tenax Provides Business and Development Updates with FY23 Financial Results
    Tenax Provides Business and Development Updates with FY23 Financial Results

    28 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/03/28/2854007/0/en/Tenax-Therapeutics-Provides-Business-and-Clinical-Development-Updates-with-Full-Year-2023-Financial-Results.html

    GLOBENEWSWIRE
    28 Mar 2024
    Share Share
    Tenax Therapeutics Announces Oral Presentation of Levosimendan
    Tenax Therapeutics Announces Oral Presentation of Levosimendan

    29 Feb 2024

    // PRESS RELEASE

    https://feeds.issuerdirect.com/news-release.html?newsid=6432598367320275

    PRESS RELEASE
    29 Feb 2024
    Share Share
    Tenax Announces License Amendment that Expands Rights to Levosimendan
    Tenax Announces License Amendment that Expands Rights to Levosimendan

    20 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/20/2831850/0/en/Tenax-Therapeutics-Announces-Global-License-Amendment-that-Significantly-Expands-Rights-to-Levosimendan.html

    GLOBENEWSWIRE
    20 Feb 2024
    Share Share